Tamara Meijer

Ms. Tamara Meijer

Chemistry and Pharmaceutical Sciences, Vrije Universiteit Amsterdam, Amsterdam, Noord-Holland, The Netherlands
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 June 2024 in Cells
Verified
Journal Article
Open access
PDF file
Tamara MeijerTamara Meijer
Tamara Meijer
DPDaniel da Costa Pereira
Daniel da Costa Pereira
OKOlivia C. Klatt
Olivia C. Klatt
JBJoanne Buitenhuis
Joanne Buitenhuis
PJPaul Jennings
Paul Jennings
AWAnja Wilmes
Anja Wilmes
The polarised expression of specific transporters in proximal tubular epithelial cells is important for the renal clearance of many endogenous and exogenous compounds. Thus, ideally, the in vitro tools utilised for predictions would have a similar expression of apical and basolateral xenobiotic transporters as in vivo. Here, we assessed the functionality of organic cation and anion transporters in proximal tubular-like cells (PTL) differentiated from human induced pluripotent stem cells (iPSC), primary human proximal tubular epithelial cells (PTEC), and telomerase-immortalised human renal proximal tubular epithelial cells (RPTEC/TERT1). Organic cation and anion transport were studied using the fluorescent substrates 4-(4-(dimethylamino)styryl)-N-methylpyridinium iodide (ASP) and 6-carboxyfluorescein (6-CF), respectively. The level and rate of intracellular ASP accumulation in PTL following basolateral application were slightly lower but within a 3-fold range compared to primary PTEC and RPTEC/TERT1 cells. The basolateral uptake of ASP and its subsequent apical efflux could be inhibited by basolateral exposure to quinidine in all models. Of the three models, only PTL showed a modest preferential basolateral-to-apical 6-CF transfer. These results show that organic cation transport could be demonstrated in all three models, but more research is needed to improve and optimise organic anion transporter expression and functionality.

22 August 2023 in Current Protocols
Verified
Journal Article
Open access
Tamara MeijerTamara Meijer
Tamara Meijer
ENElisabeth Naderlinger
Elisabeth Naderlinger
PJPaul Jennings
Paul Jennings
AWAnja Wilmes
Anja Wilmes
Recently, we have developed a protocol to differentiate human induced pluripotent stem cells (iPSC) into proximal tubular‐like cells (PTL) (Chandrasekaran et al., 2021). These cells express proximal tubular‐specific markers, including megalin, and form a polarized monolayer expressing tight junction proteins, including ZO‐3 and occludin. Furthermore, PTL display functional properties, including megalin‐facilitated endocytosis, P‐glycoprotein (ABCB1) efflux, and respond to parathyroid hormone. Here, we report step‐by‐step protocols to culture iPSC prior to differentiation (Basic Protocol 1), to differentiate PTL from iPSC (Basic Protocol 2), and to passage and freeze‐thaw PTL (Basic Protocol 3). Additionally, we provide a protocol (Basic Protocol 4) to culture PTL on microporous growth supports (transwells). Immunofluorescence stainings for characteristic markers, including megalin, are shown for unpassaged (Basic Protocol 2) and passaged (Basic Protocol 3) PTL. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC.Basic Protocol 1: iPSC cultureBasic Protocol 2: iPSC‐derived PTL differentiationBasic Protocol 3: PTL passaging, culturing, and freezingBasic Protocol 4: PTL culturing on transwellsSupport Protocol 1: Preparation of Geltrex‐coated cell culture platesSupport Protocol 2: Preparation of RPTEC/TERT1 or fHDF/TERT166‐ECM‐coated cell culture platesSupport Protocol 3: Preparation of human collagen IV‐coated cell culture platesSupport Protocol 4: Immunofluorescence staining

1 February 2025 in Toxicology in Vitro
Verified
Journal Article
Open access
Tamara MeijerTamara Meijer
Tamara Meijer
BBBas ter Braak
Bas ter Braak
LLLiesanne Loonstra-Wolters
Liesanne Loonstra-Wolters
SKSteven J. Kunnen
Steven J. Kunnen
BIBarira Islam
Barira Islam
AWAnja Wilmes
Anja Wilmes
The potent dihydroorotate dehydrogenase (DHODH) inhibitor brequinar has been investigated as an anticancer, immunosuppressive, and antiviral pharmaceutical agent. However, its toxicity is still poorly understood. We investigated the cellular responses of primary human hepatocytes (PHH) and telomerase-immortalised human renal proximal tubular epithelial cells (RPTEC/TERT1) after a single 24-h exposure up to 100 μM brequinar. Additionally, RPTEC/TERT1 cells underwent repeated daily exposure for five consecutive days at 0.3, 3, and 20 μM. Transcriptomic analysis revealed that PHH were less sensitive to brequinar treatment than RPTEC/TERT1 cells. Upregulation of various phase I and II drug-metabolising enzymes, particularly Cytochrome P450 (CYP) 1 A and 3 A enzymes, in PHH suggests potential detoxification. Furthermore, brequinar exposure led to a significant upregulation of several stress response pathways in PHH and RPTEC/TERT1 cells, including the unfolded protein response, Nrf2, p53, and inflammatory responses. RPTEC/TERT1 cells exhibited greater sensitivity to brequinar at 0.3 μM with repeated exposure compared to a single exposure. Furthermore, brequinar could impair the mitochondrial respiration of RPTEC/TERT1 cells after 24 h. This study provides new insights into the differential responses of PHH and RPTEC/TERT1 cells in response to brequinar exposure and highlights the biological relevance of implementing repeated dosing regimens in in vitro studies.

21 October 2026 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
BIBarira Islam
Barira Islam
JIJenny Irwan
Jenny Irwan
LWLukas Wijaya
Lukas Wijaya
BBBas ter Braak
Bas ter Braak
AJAmer Jamalpoor
Amer Jamalpoor
SESylvia E. Escher
Sylvia E. Escher

30 September 2026 in Archives of Toxicology
Verified
Journal Article
Open access
PDF file
BIBarira Islam
Barira Islam
JIJenny Irwan
Jenny Irwan
LWLukas Wijaya
Lukas Wijaya
BBBas ter Braak
Bas ter Braak
AJAmer Jamalpoor
Amer Jamalpoor
SESylvia E. Escher
Sylvia E. Escher
This work explores the applicability of new approach methodologies (NAMs) using a read-across approach to predict systemic toxicity with liver as the critical target organ, and derive a point of departurefor the target compound (TC) difenoconazole. Eight conazoles were used as source compounds (SCs), alongside metabolites hydroxyitraconazole and 1,2,4-triazole. The case study was structured according to the Alternative Safety Profiling Algorithm (ASPA) workflow developed within the RISK-HUNT3R project. Hierarchical clustering using chemical fingerprints identified similarity of different SCs to the TC, supporting their inclusion in the read-across analysis. A broad screening panel of NAMs, including nuclear receptor reporter assays, ToxProfiler, Cell Painting PLUS, transcriptomics in primary human hepatocytes and H295R steroidogenesis assays, was used to characterize biological activity of the TC and SCs and to substantiate the structure-based read-across. In a first prediction round, the nearest neighbour quantitative read-across approach (based on allometrically-scaled human lowest-observed-adverse-effect levels (LOAELs) of the SC) was used to predict 6.57 mg/kg/day as the LOAEL of the TC. This closely aligned with the in vivo-based value of 4.88 mg/kg/day. In a second approach, data from NAMs were used to predict human equivalent dose (HED), and the respective LOAELs of SC and TC, based on physiologically based kinetic modelling with quantitative in vitro to in vivo extrapolation. The HED derived from NAMs was approximately ten-fold lower than the LOAELs from traditional approaches. This case study illustrates suitable (ASPA-guided) approaches as well as the toxicological applicability of a NAM-based read-across assessment to obtain safe/conservative estimates of toxicity. Graphical Abstract A stepwise procedure was used in this work for assessment of systemic toxicity of the target compound, difenoconazole, using a read-across approach